Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JUN
REST API REST API
Homo sapiens
JUN is differentially expressed in 360 experiments: 145 organism parts: bone marrow, lung, ... (143 more);, 215 disease states: normal, glioblastoma, ... (213 more);, 111 cell types 478 cell lines 64 compound treatments and 80 other conditions.
Synonyms AP-1, c-Jun
Orthologs F7B9Z5_CIOIN (Ciona intestinalis)   E1C766_CHICK (Gallus gallus)   Q08DH1_BOVIN (Bos taurus)   jun (Danio rerio)   Jun (Mus musculus)   Jun (Rattus norvegicus)   Jra (Drosophila melanogaster)   jun (Xenopus laevis)   JUN (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, Toll signaling pathway, cytosol, response to hydrogen peroxide, transcriptional repressor complex, DNA binding, negative regulation of transcription, DNA-dependent, negative regulation of DNA binding, protein binding, cellular process, regulation of transcription, DNA-dependent, nuclear chromatin, double-stranded DNA binding, negative regulation of cell proliferation, innate immune response, transcription, DNA-dependent, positive regulation of cell proliferation, negative regulation of apoptosis, nuclear chromosome, transforming growth factor beta receptor signaling pathway, stress-activated MAPK cascade, transcription from RNA polymerase II promoter, positive regulation of apoptosis, transcription factor binding, learning, sequence-specific DNA binding, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, response to cAMP, transcription coactivator activity, regulation of cell cycle, nucleus, response to lipopolysaccharide, aging, positive regulation of DNA replication, transcription factor complex, response to drug, protein homodimerization activity, circadian rhythm, nucleoplasm, response to radiation, positive regulation of transcription, DNA-dependent, response to mechanical stimulus, Rho GTPase activator activity, negative regulation of neuron apoptosis, outflow tract morphogenesis, toll-like receptor 4 signaling pathway, response to cytokine stimulus, leading edge cell differentiation, toll-like receptor signaling pathway, positive regulation by host of viral transcription, membrane depolarization, axon regeneration, negative regulation by host of viral transcription, cellular response to calcium ion, toll-like receptor 3 signaling pathway, positive regulation of fibroblast proliferation, cellular response to potassium ion starvation, release of cytochrome c from mitochondria, monocyte differentiation, liver development, response to organic substance, positive regulation of endothelial cell proliferation, toll-like receptor 2 signaling pathway, positive regulation of neuron apoptosis, positive regulation of monocyte differentiation, positive regulation of smooth muscle cell proliferation, MyD88-dependent toll-like receptor signaling pathway, R-SMAD binding, SMAD protein signal transduction, microglial cell activation, sequence-specific DNA binding transcription factor activity, MyD88-independent toll-like receptor signaling pathway, regulation of sequence-specific DNA binding transcription factor activity, SMAD protein import into nucleus, negative regulation of protein autophosphorylation, response to organic cyclic compound, transcription regulatory region DNA binding, positive regulation of Rho GTPase activity, toll-like receptor 1 signaling pathway, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term bZIP_1, bZIP_2, Leuzip_Jun, JNK, TF_bZIP
UniProt Accession P05412
Search EB-eye ENSG00000177606
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
Jurkat
2
E-MTAB-62, E-MEXP-2197
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HT1080
2
E-MTAB-37, E-GEOD-20089
LNCaP
2
E-GEOD-14464, E-GEOD-14990
MCF-7
2
E-GEOD-20081, E-GEOD-5823
MOLT4
2
E-MTAB-37, E-MTAB-62
472 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (53 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-3982, E-GEOD-8286, E-GEOD-360
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-AFMX-5
centroblast
2
E-TABM-702, E-GEOD-15271
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (68 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-MTAB-37, E-GEOD-6014, E-MTAB-62, E-GEOD-4412 ... (5 experiments)
cervical carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-5823
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
control
3
E-GEOD-20602, E-GEOD-16363, E-GEOD-21912
melanoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-7307
lung adenocarcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514, E-MEXP-231
209 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (37 experiments)

Factor Value U/D Experiments
none
4
10
E-TABM-782, E-TABM-868, E-GEOD-20719, E-GEOD-412, E-MEXP-2285, ... (14 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-GEOD-3720, E-TABM-868
all-trans retinoic acid
1
E-GEOD-995
U0126
1
E-GEOD-697
sapphyrin PCI-2054
1
E-GEOD-6400
58 more value(s).


Age years

studied in E-TABM-783

Factor Value U/D Experiments
n/a
1
1
E-TABM-783
1
1
E-TABM-783


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-1692, E-MEXP-1273, ... (19 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-23984, E-GEOD-11428, E-GEOD-12710

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16193, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.317 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM